Subtype
Malignant Intestinal Neoplasm
CI-CAN-00001137Explore in graph →
1,666 active trials21 approved drugs383 evidence items
- NCIt
- C4572
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001137Explore in graph →
Clinical trials
7,773 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (772)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07559760 | New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer | recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07555678 | Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase(Chase) | recruiting | Phase 2 | 241 | Fudan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06356584 | Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases | recruiting | Phase 2 | 62 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06589830 | TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer | recruiting | Phase 2 | 80 | Suzhou Teligene Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07381309 | Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM(VVSHIP) | not yet recruiting | Phase 2 | 114 | Jun HuangOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06002789 | Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC | recruiting | Phase 2 | 17 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06428487 | Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer | completed | Phase 2 | 30 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06204094 | Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer(CASINOs) | recruiting | Phase 2 | 37 | Jinhua Central HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07542262 | Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers(NIVO402025) | enrolling by invitation | Phase 2 | 128 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07549906 | Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study | not yet recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 0 | Apr 24, 2026 | clinicaltrials |
| NCT06475352 | Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme(FUDOSE) | recruiting | Phase 2 | 400 | UNICANCEROTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03981146 | A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer(ANICCA) | completed | Phase 2 | 35 | University of BirminghamOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT07543848 | A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer | not yet recruiting | Phase 2 | 20 | Chongqing University Cancer HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07407647 | Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer | recruiting | Phase 2 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02437851 | Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection | completed | Phase 2 | 16 | AIDS Malignancy ConsortiumNETWORK | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06280495 | Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | recruiting | Phase 2 / Phase 3 | 156 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06760702 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers(TEJAS-2) | terminated | Phase 2 | 29 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07405476 | Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment | recruiting | Phase 2 | 38 | Emory UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07523763 | Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer(NIVO1002024) | active not recruiting | Phase 2 | 30 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537998 | Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial. | recruiting | Phase 2 / Phase 3 | 160 | Pei-Rong DingOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT04355156 | Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer(AXMUS-C) | completed | Phase 2 | 52 | Imperial College LondonOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06569368 | Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06669572 | Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment | recruiting | Phase 2 | 35 | University of ChicagoOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07353645 | KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 49 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07527026 | A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer | recruiting | Phase 2 | 44 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07527520 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial | not yet recruiting | Phase 2 | 165 | Fudan UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02151019 | Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer(TRI-LARC) | terminated | Phase 1 / Phase 2 | 94 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02688712 | ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | active not recruiting | Phase 2 | 50 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03259035 | NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer | completed | Phase 2 | 58 | Canadian Cancer Trials GroupNETWORK | 2 | Apr 9, 2026 | clinicaltrials |
| NCT07042685 | Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 | 50 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06162650 | Total Neoadjuvant Therapy in Rectal Cancer | recruiting | Phase 2 | 42 | National Cheng-Kung University HospitalOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07506109 | A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer | recruiting | Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07515820 | SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study | not yet recruiting | Phase 2 | 12 | Meng QiuOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation(ART-Hypo) | not yet recruiting | Phase 2 | 264 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06152523 | Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer(MONAMI) | withdrawn | Phase 2 | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07510932 | Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)(FIRST-K) | not yet recruiting | Phase 2 | 88 | Korea University Anam HospitalOTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT07511972 | Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | withdrawn | Phase 2 | 0 | NGM Biopharmaceuticals, IncINDUSTRY | 0 | Apr 6, 2026 | clinicaltrials |
| NCT06281405 | CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer(TORCH-iTNT) | recruiting | Phase 2 | 192 | Fudan UniversityOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07509398 | FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 220 | Shanghai 10th People's HospitalOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT07509424 | Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance | not yet recruiting | Phase 2 | 29 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT05515796 | Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors | completed | Phase 2 | 189 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06553885 | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | recruiting | Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | withdrawn | Phase 2 | 0 | Eric Jacobsen, MDOTHER | 0 | Apr 1, 2026 | clinicaltrials |
| NCT07033026 | An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. | recruiting | Phase 2 | 136 | NGM Biopharmaceuticals, IncINDUSTRY | 4 | Apr 1, 2026 | clinicaltrials |
| NCT07505472 | Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria(STARS-RC10) | recruiting | Phase 2 / Phase 3 | 212 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 30, 2026source: clinicaltrials